



## Announcement Summary

**Entity name**

KAZIA THERAPEUTICS LIMITED

**Date of this announcement**

Tuesday November 16, 2021

**The +securities the subject of this notification are:**

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

**Total number of +securities to be issued/transferred**

<b>ASX +security code</b>	<b>Security description</b>	<b>Total number of +securities to be issued/transferred</b>	<b>Issue date</b>
New class - code to be confirmed	FY20 options	1,000,000	16/11/2021
New class - code to be confirmed	FY21 options	1,500,000	16/11/2021
New class - code to be confirmed	Employee options expiring 16/11/2026	800,000	16/11/2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

KAZIA THERAPEUTICS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

**1.2 Registered number type**

ACN

**Registration number**

063259754

**1.3 ASX issuer code**

KZA

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

16/11/2021



Part 2 - Issue details

---

**2.1 The +securities the subject of this notification are:**

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

**2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:**

does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

### New +securities issued under an +employee incentive scheme

**ASX +security code**

**+Security description**

**+Security type**

**ISIN code**
**Date the +securities the subject of this notification were issued**

**Will all the +securities issued in this class rank equally in all respects from their issue date?**
 Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**
 Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
<input type="text" value="Dr James Garner"/>	<input type="text" value="Dr James Garner"/>	1,000,000

**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**
 Yes

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**


### Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 1.69000000	16/11/2025

**Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option**

**Description**



Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

[https://www.kaziatherapeutics.com/site/file/7/view/200906\\_Employee\\_Share\\_Option\\_Plan.pdf](https://www.kaziatherapeutics.com/site/file/7/view/200906_Employee_Share_Option_Plan.pdf)

Any other information the entity wishes to provide about the +securities the subject of this notification

#### Issue details

#### Number of +securities

1,000,000

#### New +securities issued under an +employee incentive scheme

##### ASX +security code

New class - code to be confirmed

##### +Security description

FY21 options

##### +Security type

Options

##### ISIN code

#### Date the +securities the subject of this notification were issued

16/11/2021

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

##### Name of KMP

Dr James Garner

##### Name of registered holder

Dr James Garner

##### Number of +securities

1,500,000

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

Yes

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

[https://www.kaziatherapeutics.com/site/file/7/view/200906\\_Employee\\_Share\\_Option\\_Plan.pdf](https://www.kaziatherapeutics.com/site/file/7/view/200906_Employee_Share_Option_Plan.pdf)



## Options Details

<b>+Security currency</b>	<b>Exercise price</b>	<b>Expiry date</b>
AUD - Australian Dollar	AUD 2.24000000	16/11/2025

**Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option**

Other

**Description**

FY21 CEO options

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**[https://www.kaziatherapeutics.com/site/file/7/view/200906\\_Employee\\_Share\\_Option\\_Plan.pdf](https://www.kaziatherapeutics.com/site/file/7/view/200906_Employee_Share_Option_Plan.pdf)**Any other information the entity wishes to provide about the +securities the subject of this notification**

## Issue details

**Number of +securities**

1,500,000

**New +securities issued under an +employee incentive scheme****ASX +security code**

New class - code to be confirmed

**+Security description**

Employee options expiring 16/11/2026

**+Security type**

Options

**ISIN code****Date the +securities the subject of this notification were issued**

16/11/2021

**Will all the +securities issued in this class rank equally in all respects from their issue date?** Yes



Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Dr John Friend	Dr John Friend	800,000

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

Yes

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

[https://www.kaziatherapeutics.com/site/file/7/view/200906\\_Employee\\_Share\\_Option\\_Plan.pdf](https://www.kaziatherapeutics.com/site/file/7/view/200906_Employee_Share_Option_Plan.pdf)

#### Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 1.56000000	16/11/2026

Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option

Other

#### Description

Employee options

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

[https://www.kaziatherapeutics.com/site/file/7/view/200906\\_Employee\\_Share\\_Option\\_Plan.pdf](https://www.kaziatherapeutics.com/site/file/7/view/200906_Employee_Share_Option_Plan.pdf)

Any other information the entity wishes to provide about the +securities the subject of this notification

#### Issue details

Number of +securities

800,000



## Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:  
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

## 4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
KZA : ORDINARY FULLY PAID	132,552,209

## 4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
KZAAG : OPTION EXPIRING 04-JAN-2025 EX \$1.69	200,000
KZAAF : OPTION EXPIRING 09-NOV-2024 EX \$1.132	1,200,000
KZAAD : OPTION EXPIRING 13-NOV-2023 EX \$0.4925	1,200,000
KZAAB : OPTION EXPIRING 09-NOV-2024 EX \$0.8812	800,000
KZAAE : OPTION EXPIRING 13-JAN-2025 EX \$0.8812	200,000
KZAAC : CONVERTIBLE NOTES	1,865,000
KZAAA : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	330,500
KZAAH : OPTION EXPIRING 21-JUN-2026 EX \$1.365	100,000
New class - code to be confirmed : FY20 options	1,000,000
New class - code to be confirmed : FY21 options	1,500,000
New class - code to be confirmed : Employee options expiring 16/11/2026	800,000





Part 5 - Other Listing Rule requirements

---

**5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?**

No

**5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

No

**5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

No

**5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

N/A